These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17274394)

  • 41. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease.
    Arnáiz E; Almkvist O
    Acta Neurol Scand Suppl; 2003; 179():34-41. PubMed ID: 12603249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of a cognitive rehabilitation program in mild dementia (MD) and mild cognitive impairment (MCI): a case control study.
    Talassi E; Guerreschi M; Feriani M; Fedi V; Bianchetti A; Trabucchi M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():391-9. PubMed ID: 17317481
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mild cognitive impairment and development of dementia].
    Luck T; Busse A; Hensel A; Angermeyer MC; Riedel-Heller SG
    Psychiatr Prax; 2008 Oct; 35(7):331-6. PubMed ID: 18504687
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mild cognitive impairment (MCI): a historical perspective.
    Reisberg B; Ferris SH; Kluger A; Franssen E; Wegiel J; de Leon MJ
    Int Psychogeriatr; 2008 Feb; 20(1):18-31. PubMed ID: 18031593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conversion of mild cognitive impairment to dementia in elderly subjects: a preliminary study in a memory and cognitive disorder unit.
    Maioli F; Coveri M; Pagni P; Chiandetti C; Marchetti C; Ciarrocchi R; Ruggero C; Nativio V; Onesti A; D'Anastasio C; Pedone V
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():233-41. PubMed ID: 17317458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mild Cognitive Impairment and Mild Dementia: The Role of
    Tomino C; Ilari S; Solfrizzi V; Malafoglia V; Zilio G; Russo P; Proietti S; Marcolongo F; Scapagnini G; Muscoli C; Rossini PM
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33915701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mild cognitive impairment (MCI): characteristics, risk factors and prevention].
    Halperin I; Korczyn AD
    Harefuah; 2006 Mar; 145(3):229-34, 243. PubMed ID: 16599323
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Ginkgo extract in people with declining mental performance].
    Kaschel R
    Pharm Unserer Zeit; 2009; 38(5):432-9. PubMed ID: 19711319
    [No Abstract]   [Full Text] [Related]  

  • 49. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy.
    Winblad B; Wimo A; Engedal K; Soininen H; Verhey F; Waldemar G; Wetterholm AL; Haglund A; Zhang R; Schindler R
    Dement Geriatr Cogn Disord; 2006; 21(5-6):353-63. PubMed ID: 16508298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia.
    Fischer P; Jungwirth S; Zehetmayer S; Weissgram S; Hoenigschnabl S; Gelpi E; Krampla W; Tragl KH
    Neurology; 2007 Jan; 68(4):288-91. PubMed ID: 17242334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. From mild cognitive impairment to Alzheimer's disease - influence of homocysteine, vitamin B12 and folate on cognition over time: results from one-year follow-up.
    Siuda J; Gorzkowska A; Patalong-Ogiewa M; Krzystanek E; Czech E; Wiechuła B; Garczorz W; Danch A; Jasińska-Myga B; Opala G
    Neurol Neurochir Pol; 2009; 43(4):321-9. PubMed ID: 19742390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication].
    Blume J; Kieser M; Hölscher U
    Vasa; 1996; 25(3):265-74. PubMed ID: 8967154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study.
    Canevelli M; Adali N; Kelaiditi E; Cantet C; Ousset PJ; Cesari M;
    Phytomedicine; 2014 May; 21(6):888-92. PubMed ID: 24548724
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Conversion from MCI (Mild Cognitive Impairment) to Alzheimer's disease: diagnostic options and predictors].
    Defranceso M; Schocke M; Messner HJ; Deisenhammer EA; Hinterhuber H; Marksteiner J; Weiss EM
    Neuropsychiatr; 2010; 24(2):88-98. PubMed ID: 20605004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
    Campanozzi MD; Casali E; Neviani F; Martini E; Neri M
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():91-6. PubMed ID: 17317439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of tanakan on psychophysiological status of patients with asthenic disorders].
    Neznamov GG; Teleshova ES; Siuniakov SA; Morozov IS; Davydova IA; Zhirnov EN
    Eksp Klin Farmakol; 2002; 65(1):19-23. PubMed ID: 12025777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized controlled pilot trial: the effects of EGb 761 on information processing and executive function in multiple sclerosis.
    Diamond BJ; Johnson SK; Kaufman M; Shiflett SC; Graves L
    Explore (NY); 2013; 9(2):106-7. PubMed ID: 23452713
    [No Abstract]   [Full Text] [Related]  

  • 58. Sensitivity to change of composite and frequency scores of the neuropsychiatric inventory in mild cognitive impairment.
    Cummings JL; Tribanek M; Hoerr R
    Int Psychogeriatr; 2014 Nov; 26(11):1871-4. PubMed ID: 24990088
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Use of Tanakan (EGb 761) in ophthalmology].
    Cernák A
    Cesk Slov Oftalmol; 2002 Nov; 58(6):402-3. PubMed ID: 12629856
    [No Abstract]   [Full Text] [Related]  

  • 60. [Treatment of asthenic disorders with tanakan].
    Milopol'skaia IM
    Ter Arkh; 2001; 73(10):45-7. PubMed ID: 11763515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.